CD25+CD4+ regulatory t-cells in cancer

David C. Linehan, Peter S. Goedegebuure

Research output: Contribution to journalReview articlepeer-review

107 Scopus citations

Abstract

Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accrual of Treg through several mechanisms involving activation of naturally occurring T reg as well as conversion of non-Treg into T reg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.

Original languageEnglish
Pages (from-to)155-168
Number of pages14
JournalImmunologic Research
Volume32
Issue number1-3
DOIs
StatePublished - 2005

Keywords

  • Anticancer immunity
  • Cancer
  • Depletion
  • Foxp3
  • Regulatory t-cells
  • Suppression
  • Transforming growth factor-β

Fingerprint

Dive into the research topics of 'CD25+CD4+ regulatory t-cells in cancer'. Together they form a unique fingerprint.

Cite this